Phase II study of 5'-deoxy-5-fluorouridine (doxifluridine) in advanced malignant melanoma.
Forty-two patients with malignant melanoma were treated with doxifluridine, 4000 mg/m2 daily X 5, repeated every 3 weeks. The daily dose was reduced to 3000 mg/m2 in patients who had experienced severe myelosuppression with prior chemotherapy. A total of 35 patients were evaluable for response, and 25 of these received two or more courses. Two responses were observed. Toxicity mainly took the form of nausea, vomiting, stomatitis, dizziness, ataxia, and fatigue. Mild leukopenia was frequent (43%). Nadir counts less than 1.5 X 10(9)/l leukocytes or 50 X 10(9)/l platelets were seen in 7% and 2% of the courses respectively. Doxifluridine has no useful activity against malignant melanoma.
Alberto
P
P
Rozencweig
M
M
Clavel
M
M
Siegenthaler
P
P
Cavalli
F
F
Gundersen
S
S
Bruntsch
U
U
Renard
J
J
Pinedo
H
H
D004341:Drug Evaluation; D005467:Floxuridine / Q000627:therapeutic use* / Q000633:toxicity; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*
D005467:Floxuridine; C025034:doxifluridine